Compare Becton Dickinson and Co (BDX) vs Global E Online Ltd (GLBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Global E Online Ltd — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Global E Online Ltd trades at $38.51 (market cap $6.51B). The key difference: Becton Dickinson and Co is far larger — about 6.4× Global E Online Ltd's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.
| BDX | GLBE | |
|---|---|---|
Market Cap | $41.51B | $6.51B |
Sector | Health | Technology |
52-Week High | $185.39 | $41.59 |
52-Week Low | $135.49 | $27.54 |
Enterprise Value | $57.97B | $5.98B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
GLBE trades at $38.68, up 0.52% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q1 2026 results with revenue growth of 33% year-over-year and raised full-year guidance, achieving a 'Rule of 50' metric. Recent acquisition of Passport enhances logistics capabilities, supporting future growth. Valuation remains elevated with a P/E of 57.84 and P/S of 6.7, reflecting high growth expectations.
Outlook is positive driven by robust merchant demand and cross-border expansion, though risks include execution of acquisitions and competitive pressures. Analysts are unanimously bullish with a $38 consensus target, near the current price. Stock investors should monitor earnings consistency and integration success for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →
